QUESTLAB (QUESTLAB) fundamentals
QUESTLAB is a listed company, part of the Pharmaceuticals sector, listed on the NSE as QUESTLAB (ISIN INE0TNW01017). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What QUESTLAB does
Quest Laboratories Limited is engaged in the business of manufacturing pharmaceutical formulations across a broad spectrum, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more. It produces a variety of products, comprising ethical drugs, generic drugs, and over-the-counter drugs (OTC). These products are available in various forms, such as tablets, liquid orals, oral dry powders, oral powders (ORS), ointments, and external liquids. The tablets include Cetirizine Hydrochloride Tablet IP 10 mg, Zinc Sulphate Dispersible Tablet IP, Diclofenac Sodium Tablet BP, and others. It offers dry syrup and suspension, such as Ferrous Sulphate & Folic Acid Syrup, Albendazole Suspension IP, Zinc Oral Solution USP, Alpha Amilase & Pepsine, Sucralfate Suspension, and others. Its ointments include Silver Sulphadiazine Cream IP, Diclofenac Diethylamino IP Gel, and Povidone Iodine Ointment USP.
Valuation and market data
| Last close | ₹84.70 |
|---|---|
| Market capitalisation | ₹139 crore |
| Enterprise value | ₹141 crore |
| P/E (TTM) | 0.00 |
| Price to book | 1.70 |
| Price to sales (TTM) | 1.21 |
| Book value per share | ₹49.91 |
| Dividend yield | 0.00% |
| Sector | Pharmaceuticals |
| Industry | — |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹114 crore | ₹18 crore | ₹15 crore | 0.00 |
| Mar 2025 | ₹108 crore | ₹19 crore | ₹14 crore | 8.28 |
| Mar 2024 | ₹83 crore | ₹14 crore | ₹10 crore | 6.16 |
| Mar 2023 | ₹62 crore | ₹7 crore | ₹5 crore | 46.76 |
| Mar 2022 | ₹60 crore | ₹6 crore | ₹4 crore | 38.05 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Mar 2026:
| Promoters | 66.8% |
|---|---|
| Foreign institutions (FII) | 0.6% |
| Mutual funds | 0.0% |
| Other domestic institutions | 2.0% |
| Retail and others | 30.6% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.